Lantern Pharma (NASDAQ: LTRN), an AI company developing targeted cancer therapies using its proprietary RADR AI and machine learning platform, announced that management will present at the ThinkEquity Conference on Oct. 15, 2026, at 3:30 p.m. ET at the Mandarin Oriental in New York City. The presentation will be available via live webcast, and Lantern Pharma management will be available for one-on-one investor meetings throughout the conference.
The presentation comes as Lantern Pharma continues to advance its clinical-stage pipeline, which includes LP-184 (zirdafulven), LP-300, and LP-284, along with its central-nervous-system-focused subsidiary, Starlight Therapeutics, and its AI subsidiary, Open-Medicine AI. The company’s RADR platform integrates large-scale genomic and biological data with advanced machine learning to identify patients most likely to benefit from its therapies and to guide biomarker-driven clinical development.
For investors and industry observers, the ThinkEquity Conference appearance represents an opportunity to gain deeper insight into Lantern Pharma’s strategy to transform the cost, pace, and precision of oncology drug development. The one-on-one meetings could also provide institutional investors with direct access to management, potentially influencing investment decisions. The live webcast ensures that a broader audience can follow the presentation in real time.
Lantern Pharma’s AI-driven approach addresses a critical challenge in oncology: the high failure rate and expense of clinical trials. By using RADR to select patients more likely to respond, the company aims to increase the probability of success and reduce development timelines. If successful, this could lead to more effective and personalized cancer treatments, benefiting patients and potentially lowering healthcare costs over time.
The announcement is being distributed through InvestorWire, a specialized communications platform with a focus on advanced wire-grade press release syndication. InvestorWire is part of the Dynamic Brand Portfolio at IBN, which offers access to a vast network of wire solutions, article and editorial syndication to 5,000+ outlets, enhanced press release enhancement, social media distribution, and tailored corporate communications solutions.
For those unable to attend in person, the live webcast will provide real-time access to the presentation. Additional details can be found in the full press release at https://ibn.fm/hmTGq, and ongoing updates about Lantern Pharma are available in the company’s newsroom at https://ibn.fm/LTRN. Investors and industry watchers will be keen to see how Lantern Pharma’s AI platform continues to shape its clinical programs and whether the conference sparks new interest in the company’s vision for the future of oncology drug development.
